{
    "clinical_study": {
        "@rank": "90625", 
        "arm_group": [
            {
                "arm_group_label": "ETC-1002", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety, atorvastatin pharmacokinetics, and LDL-C lowering\n      efficacy of ETC-1002 versus placebo in hypercholesterolemic subjects on background therapy\n      of atorvastatin 10 mg."
        }, 
        "brief_title": "A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For subjects on current daily statin therapy - LDL-C 100-220 mg/dL and triglycerides\n             <350 mg/dL (prior to switching to sponsor -provided atorvastatin 10 mg/day and\n             stopping all other lipid-regulating drugs and supplements) at the S1 Visit,\n\n          -  For subjects not on current daily statin therapy - LDL-C \u2265 110 mg/dL and \u2264 220 mg/dL\n\n        Exclusion Criteria:\n\n          -  Acute significant cardiovascular disease\n\n          -  Uncontrolled hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779453", 
            "org_study_id": "1002-007"
        }, 
        "intervention": [
            {
                "arm_group_label": "ETC-1002", 
                "description": "Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day", 
                "intervention_name": "ETC-1002", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Atorvastatin", 
            "Drug-drug interaction", 
            "Combination therapy"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40213"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23294"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug Interaction Study to Evaluate the Safety, Tolerability and Effect on Atorvastatin Pharmacokinetics of ETC-1002 Added to Atorvastatin 10 mg/Day in Subjects With Hypercholesterolemia", 
        "other_outcome": {
            "measure": "Area under the plasma concentration versus time curve (AUC) and peak plasma concentration (Cmax) of ETC-1002 and its active metabolite", 
            "safety_issue": "No", 
            "time_frame": "4 and 8 weeks"
        }, 
        "overall_official": {
            "affiliation": "Esperion Therapeutics, Inc.", 
            "last_name": "Noah Rosenberg, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of atorvastatin and its active metabolites", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Peak plasma concentration (Cmax) of atorvastatin and its active metabolites", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Number of subjects with adverse events, clinical lab abnormalities and other safety findings", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779453"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent change in LDL-C", 
                "safety_issue": "No", 
                "time_frame": "2, 4, 6 and 8 weeks"
            }, 
            {
                "measure": "Percent change in other lipids and cardio-metabolic risk factors", 
                "safety_issue": "No", 
                "time_frame": "2, 4, 6 and 8 weeks"
            }
        ], 
        "source": "Esperion Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Esperion Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}